Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amerise Biosciences's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-0.01.
During the past 13 years, Amerise Biosciences's highest 3-Year average EPS without NRI Growth Rate was 166.30% per year. The lowest was -139.10% per year. And the median was 2.80% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Amerise Biosciences EPS (Diluted) Related Terms
Amerise Biosciences EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Amerise Biosciences's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531681 vs XXI, CCXI, DMII: EPS (Diluted) Comparison
For the Shell Companies subindustry, Amerise Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amerise Biosciences PE Ratio vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Amerise Biosciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Amerise Biosciences's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Amerise Biosciences's Diluted EPS for the fiscal year that ended in Mar. 2026 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amerise Biosciences (BOM:531681) has a EPS (Diluted) of ₹-0.01 as of Jun. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Amerise Biosciences and its competitors.
Is Amerise Biosciences' EPS (Diluted) too high?
Amerise Biosciences' current EPS (Diluted) is ₹-0.01. Overall, Amerise Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amerise Biosciences' EPS (Diluted) compare to XXI and CCXI?
Amerise Biosciences' EPS (Diluted) of ₹-0.01 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Diversified Financial Services company?
A good EPS (Diluted) depends on the Diversified Financial Services industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Amerise Biosciences and its competitors. Amerise Biosciences's current EPS (Diluted) is ₹-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amerise Biosciences stock overvalued right now?
Amerise Biosciences (BOM:531681) has a current EPS (Diluted) of ₹-0.01. The current EPS (Diluted) is ₹-0.01. Amerise Biosciences' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Amerise Biosciences (BOM:531681), the current EPS (Diluted) is ₹-0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531681 has been successfully added to your 
